The emergence of GLP-1 receptor agonists like semaglutide and tirzepatide has significantly altered the approach to addressing type 2 diabetes and supporting weight management. While both drugs share a shared mechanism of action – mimicking the effects of the natural hormone GLP-1 – tirzepatide possesses a novel advantage: it’s a dual agonist